Some groups speculated that the treatment based on the combination of MYO plus ALA could improve metabolic features in obese PCOS women through a new mechanism, not completely understood yet, which could be independent from the insulin pathway and centered instead on the ovary [57]. The gene discussed is INS; the disease is polycystic ovary syndrome.